Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

INTRODUCTION: Dalbavancin is a new lipoglycopeptide that is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. It has a half-life of 14.4 days, permitting intravenous treatment of acute bacterial skin and skin structure infections without the need for dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunne, Michael W., Talbot, George H., Boucher, Helen W., Wilcox, Mark, Puttagunta, Sailaja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735234/
https://www.ncbi.nlm.nih.gov/pubmed/26715497
http://dx.doi.org/10.1007/s40264-015-0374-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735234/
https://www.ncbi.nlm.nih.gov/pubmed/26715497
http://dx.doi.org/10.1007/s40264-015-0374-9

Ejemplares similares